Törüner M - Search Results

1

Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis.

Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S; VARSITY Study Group. Sands BE, et al. Among authors: toruner m. N Engl J Med. 2019 Sep 26;381(13):1215-1226. doi: 10.1056/NEJMoa1905725. N Engl J Med. 2019. PMID: 31553834 Clinical Trial.

2

Endoscopic factors in the diagnosis of colorectal dysplasia in chronic inflammatory bowel disease.

Toruner M, Harewood GC, Loftus EV Jr, Sandborn WJ, Tremaine WJ, Faubion WA, Schroeder KW, Egan LJ. Toruner M, et al. Inflamm Bowel Dis. 2005 May;11(5):428-34. doi: 10.1097/01.mib.0000158951.54388.3a. Inflamm Bowel Dis. 2005. PMID: 15867581

3

Risk factors for opportunistic infections in patients with inflammatory bowel disease.

Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ. Toruner M, et al. Gastroenterology. 2008 Apr;134(4):929-36. doi: 10.1053/j.gastro.2008.01.012. Epub 2008 Jan 11. Gastroenterology. 2008. PMID: 18294633

4

What is the importance of anti-TNF agents in the treatment of luminal (inflammatory type) Crohn's disease?

Kabaçam G, Törüner M. Kabaçam G, et al. Among authors: toruner m. Turk J Gastroenterol. 2010 Mar;21(1):107-12. doi: 10.4318/tjg.2010.0066. Turk J Gastroenterol. 2010. PMID: 20552736 Free article. Review. No abstract available.

5

Colorectal cancer in inflammatory bowel disease: results of the 3rd ECCO pathogenesis scientific workshop (I).

Sebastian S, Hernández V, Myrelid P, Kariv R, Tsianos E, Toruner M, Marti-Gallostra M, Spinelli A, van der Meulen-de Jong AE, Yuksel ES, Gasche C, Ardizzone S, Danese S. Sebastian S, et al. Among authors: toruner m. J Crohns Colitis. 2014 Jan;8(1):5-18. doi: 10.1016/j.crohns.2013.04.008. Epub 2013 May 9. J Crohns Colitis. 2014. PMID: 23664897 Review.

6

Factor V Leiden, prothrombin G20210A and MTHFR gene mutations in inflammatory bowel disease.

Törüner M, Erkan O, Soykan I, Bozdayi M, Cetinkaya H, Yurdaydin C, Uzunalimoğlu O, Ozden A. Törüner M, et al. Turk J Gastroenterol. 2004 Dec;15(4):250-2. Turk J Gastroenterol. 2004. PMID: 16249980 Free article.

7

Cytokine gene polymorphisms in Turkish patients with inflammatory bowel disease.

Celik Y, Dagli U, Kiliç MY, Törüner M, Ozen SC, Ozkan M, Soykan I, Cetinkaya H, Ulker A, Ozden A, Bozdayi AM. Celik Y, et al. Among authors: toruner m. Scand J Gastroenterol. 2006 May;41(5):559-65. doi: 10.1080/00365520500349523. Scand J Gastroenterol. 2006. PMID: 16638698

8

Can azathioprine 6-mercaptopurine treatment be withdrawn in patients with response in ulcerative colitis: what is the most appropriate time for this?

Kabaçam G, Törüner M. Kabaçam G, et al. Among authors: toruner m. Turk J Gastroenterol. 2012;23 Suppl 2:17-20. doi: 10.4318/tjg.2012.0618. Turk J Gastroenterol. 2012. PMID: 23576085 Free article. Review. No abstract available.

9

Effects of polymorphism in G2677T/A triallelic region of MDR1 gene in Turkish patients with inflammatory bowel disease.

Sapmaz A, Ozen Karatayli SC, Dağli U, Kiliç ZM, Törüner M, Celik Y, Ozkan M, Soykan I, Cetinkaya H, Ulker A, Ozden A, Bozdayi AM. Sapmaz A, et al. Among authors: toruner m. Turk J Gastroenterol. 2008 Sep;19(3):168-73. Turk J Gastroenterol. 2008. PMID: 19115152 Free article.

10

Remission of severe aplastic anemia associated with hepatitis B virus infection after viral clearance: potential role of lamivudine.

Bozkaya H, Yurdaydin C, Törüner M, Arat M, Bozdayi AM, Erekul S, Cinar K, Koç H, Uzunalimoğlu O. Bozkaya H, et al. Among authors: toruner m. Dig Dis Sci. 2002 Aug;47(8):1782-5. doi: 10.1023/a:1016444611997. Dig Dis Sci. 2002. PMID: 12184530

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

71 results

Search Page